首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Journal of drug targeting

缩写:J DRUG TARGET

ISSN:1061-186X

e-ISSN:1029-2330

IF/分区:4.7/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引1790
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Regan Charles R,Subhasis Sarangi,Aranganathan V Regan Charles R
Cancer therapy demands smarter, more targeted strategies that minimise healthy tissue damage while maximising therapeutic efficacy. This study introduces Hy-Si-IONC, a dual heat- and pH-responsive hydrogel-coated magnetic nanocluster, engin...
Qian Zhu,Wei Zhang,Junmo Yang et al. Qian Zhu et al.
The therapeutic potential of tectoridin for melasma treatment is limited by its poor aqueous solubility. To address this limitation, we developed tectoridin-loaded ethosomes using the film dispersion method, and optimized the formulation vi...
Juan Du,Xinmei Chen Juan Du
Acute liver injury (ALI) is a syndrome characterized by rapid deterioration of liver function, rapid progression, and high mortality. In this study, a liver-targeted drug delivery system, galactosylated chitosan modified Coreopsis tinctoria...
Philipp O Tsvetkov Philipp O Tsvetkov
Drug repurposing can accelerate oncology translation by leveraging approved compounds with known pharmacology; success depends on a plausible mechanism for the new indication. The microtubule cytoskeleton is a validated anticancer target, y...
Zhenhua Guan,Yi Xu,Xuyang Liang et al. Zhenhua Guan et al.
Conventional therapeutic agents for ulcerative colitis (UC) exhibit limited efficacy and toxic side effects. Although the natural compound physcion (PHY) demonstrates multi-target anti-inflammatory potential, its clinical application is con...
Lavanya N,Vijayabharathi S,Mohamed Nawfal Ibraheam A M et al. Lavanya N et al.
Breast cancer is still one of the most prevalent causes of cancer deaths globally. This is because systemic toxicity, multidrug resistance and poor tumor selectivity typically make treatment less effective. Traditional drug delivery methods...
Imran Ali,Mir Faiza,Arshad Mehmood et al. Imran Ali et al.
Molecular engineering, chemical biology and translational oncology have transformed the landscape of targeted cancer therapies. Antibody-drug conjugates (ADCs) have advanced into clinically validated platforms that combine antigen-specific ...
Kiarash Solouki,Muhammad Sohail Kiarash Solouki
Subcellular organelle targeting is changing the way nanomedicine is designed, moving the field beyond simple cellular entry toward more precise intracellular localization, controlled cargo release, and functional activity within disease-rel...
Ankith Nallapeta Amaranatha,Sateesha Shivally Boregowda,Shivanand Kalyanappa Mutta et al. Ankith Nallapeta Amaranatha et al.
Eletriptan hydrobromide (EHBr) exhibits poor oral bioavailability due to extensive first-pass metabolism by CYP3A4 and P-glycoprotein mediated efflux at the blood brain barrier. Therefore, this study was conceptualized to encapsulate EHBr i...
Reza Zolfaghari Emameh Reza Zolfaghari Emameh
Gastrointestinal (GI) malignancies are leading causes of global cancer mortality, with advanced stages showing pronounced therapeutic resistance. A key driver of this aggression is the immunosuppressive and acidic tumor microenvironment (TM...